相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
Wen-Son Hsieh et al.
CLINICAL CANCER RESEARCH (2009)
Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model
Maria Virginia C. L. Appleyard et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Outcome of Treatment of Human HeLa Cervical Cancer Cells With Roscovitine Strongly Depends on the Dosage and Cell Cycle Status Prior to the Treatment
Jozefa Wesierska-Gadek et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism
Gustavo Ortiz-Ferron et al.
CELL RESEARCH (2008)
Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB-targeting agents
Ian N. Fleming et al.
CLINICAL CANCER RESEARCH (2008)
Roscovitine Up-Regulates p53 Protein and Induces Apoptosis in Human HeLaS3 Cervix Carcinoma Cells
Jozefa Wesierska-Gadek et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
K. Bettayeb et al.
ONCOGENE (2008)
Seliciclib, a cell-cycle modulator that acts through the inhibition of cyclin-dependent kinases
Robert C. Jackson et al.
EXPERT OPINION ON DRUG DISCOVERY (2008)
The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines
Helen M. Coley et al.
GYNECOLOGIC ONCOLOGY (2007)
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
C. Benson et al.
BRITISH JOURNAL OF CANCER (2007)
Roscovitine in B-chronic lymphocytic leukemia cells: high apoptosis-inducing efficacy and synergism with alemtuzumab independent of the patients' pretreatment status
Eva Weingrill et al.
HAEMATOLOGICA (2007)
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Katia Lacrima et al.
LEUKEMIA & LYMPHOMA (2007)
Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder
Andriy O. Yurakh et al.
EUROPEAN UROLOGY (2006)
(R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastorna cells to nutlin-3-induced apoptosis
Judit Ribas et al.
EXPERIMENTAL CELL RESEARCH (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma
F Mendrzyk et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mammalian cyclin-dependent kinases
M Malumbres et al.
TRENDS IN BIOCHEMICAL SCIENCES (2005)
Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma
N Raje et al.
BLOOD (2005)
Stability, pKa and plasma protein binding of roscovitine
M Vita et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2005)
Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death
BAA Weaver et al.
CANCER CELL (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202
FI Raynaud et al.
CLINICAL CANCER RESEARCH (2005)
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphoma
K Lacrima et al.
ANNALS OF ONCOLOGY (2005)
Cyclin D1 in breast cancer pathogenesis
A Arnold et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Seliciclib (CYC202, R-roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1
DE MacCallum et al.
CANCER RESEARCH (2005)
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival
AJ Alvi et al.
BLOOD (2005)
Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat
M Vita et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2005)
Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells
IN Hahntow et al.
LEUKEMIA (2004)
Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP
EH Kim et al.
ONCOGENE (2004)
Stuck in division or passing through: What happens when cells cannot satisfy the spindle assembly checkpoint
CL Rieder et al.
DEVELOPMENTAL CELL (2004)
The cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway
SR Whittaker et al.
CANCER RESEARCH (2004)
Proteasome-mediated destruction of the cyclin A/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo
W Chen et al.
CANCER RESEARCH (2004)
Roscovitine and other purines as kinase inhihitors. From starfish oocytes to clinical trials
L Meijer et al.
ACCOUNTS OF CHEMICAL RESEARCH (2003)
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy
S Grant et al.
DRUG RESISTANCE UPDATES (2003)
In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine)
SJ McClue et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Cyclin D-dependent kinases, INK4 inhibitors and cancer
S Ortega et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2002)
Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control
T Oelgeschläger
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
To cycle or not to cycle: A critical decision in cancer
M Malumbres et al.
NATURE REVIEWS CANCER (2001)
Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer
SD Wang et al.
TETRAHEDRON-ASYMMETRY (2001)
Cyclin-dependent kinases
JW Harper et al.
CHEMICAL REVIEWS (2001)
Specific protection against breast cancers by cyclin D1 ablation
QY Yu et al.
NATURE (2001)
分享论文
